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Abstract
Background:  Embryo implantation plays a major role in embryogenesis and the outcome of pregnancy.
Plasminogen activators (PAs) have been implicated in mammalian fertilization, early stages of development and
embryo implantation. The invasion of trophoblast cells into the endometrium during the implantation process can
be blocked by inhibitors of serine proteases, illustrating the role of these enzymes in the invasion process. As in
vitro developing embryos resulted in lower implantation rate than those developed in vivo we assume that a
reduced PAs activity may lead to it. There is hardly any information regarding qualitative or quantitative
differences in expression of PAs in preimplantation embryos, or comparisons between in vivo and in vitro
developed embryos. The purpose of this study was to assess the expression of urokinase type (uPA) and tissue
type (tPA) plasminogen activators in in vivo and in vitro preimplantation development in rat embryos using
immunofluorescence confocal microscopy and computerized image analysis.
Methods: Zygotes, 2-cell, 4-cell, 8-cell, morula and blastocyst stages of development were flushed from the
reproductive tract (control groups) of Wistar rats. Zygotes were flushed and grown in vitro to the above
mentioned developmental stages and comprised the experimental groups. Immunofluorescence microscopy and
computerized image analysis were used to evaluate both qualitative (localization) and quantitative expression of
plasminogen activators.
Results:  uPA and tPA were found to be expressed in rat embryos throughout their preimplantation
development, both in vivo and in vitro. While uPA was localized mainly in the cell cytoplasm, the tPA was detected
mainly on cell surface and in the perivitelline space. In blastocysts, both in vivo and in vitro, uPA and tPA were
localized in the trophectoderm cells. Total uPA content per embryo was higher in the in vivo as compared with
the in vitro developed embryos at all stages measured. Blastocyst uPA content was significantly low as compared
with the four-cell, eight-cell, and morula stages. Total tPA content was higher in embryos developed in vivo than
those developed in vitro except for the 4-cell and 8-cell stages.
Conclusion: In vitro embryo development leads to lower PAs expression in a stage dependent manner as
compared with in vivo developing controls. The enzymes studied vary probably in the ratio of their active and
inactive forms as there is no correlation between their content and the activity observed in our previous study.
The localization of both PAs in the blastocysts' trophectoderm supports the assumption that PAs plays a role in
the implantation process in rats.
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Background
Plasminogen activators (PAs) and matrix metalloprotein-
ases (MMPs) have been implicated in mammalian game-
togenesis [1], ovulation [2,3], fertilization [4,5], early
stages of development and embryo implantation [6,7].
The PAs are serine proteases, which convert the inactive
plasminogen to the potent protease plasmin. Plasmin can
degrade directly or indirectly, through the activation of
metalloproteinase zymogens, all components of the extra-
cellular matrix [8,9]. There are two types of PAs, tissue-
type plasminogen activator (tPA) and urokinase-type
plasminogen activator (uPA). Plasminogen, its activators
and inhibitors, participate in the implantation process.
Trophoblast cells of human blastocysts cultured in vitro
produced PAs during the period corresponding to the in
vivo invasion into the endometrium [10]. In embryos of
the homozygous tw73 mouse mutant, PAs were reduced
and was concomitantly associated with implantation fail-
ure [11]. The invasion of trophoblast cells during the
implantation process could be blocked by inhibitors of
serine proteases, illustrating the role of these enzymes in
the invasion process [12,13]. In the human, embryo
implantation following in vitro fertilization and embryo
transfer (IVF-ET) is considered to play a major role in the
success of the treatment. Only 12% of the transferred
embryos are able to successfully implant [14].
In the implantation process, two major factors participate:
the uterus undergoes changes that prepare it for the arrival
and implantation of embryos, and the embryos undergo
cellular reorganization that enables them to penetrate the
endometrium and to form the placenta. We assume that
one of the reasons for low implantation rate of embryos
developed in vitro involves reduced PAs activity.
In a previous study we demonstrated differences in PAs
activities between in vivo and in vitro preimplantation
developed embryos. In both, uPA activity increased from
the zygote towards the blastocyst stage while tPA activity
remained relatively unchanged. However, tPA and uPA
activities were lower in in vitro developed embryos as
compared with in vivo developing ones, at all develop-
mental stages, which may lead to a reduced implantation
rate of in vitro developed embryos [15].
There is hardly any information regarding qualitative or
quantitative differences in expression of PAs in preim-
plantation embryos, or comparisons between in vivo and
in vitro developed embryos. Therefore, the purpose of this
study was to investigate the PAs expression and localiza-
tion during embryo development in vivo and in vitro by
immunofluorescence confocal microscopy.
Methods
The following study was approved by the Institutional
committee for animal care and ethics at Ben-Gurion Uni-
versity of the Negev, Beer-Sheva, Israel.
Animals
Mature female Wistar rats 2–3 months old, weighing 180–
230 g were used. The animals were kept in a temperature-
controlled room maintained at 22–24°C with lighting
regimen of 14 hours light 10 hours dark (light on 5:00 AM
– 7:00 PM). The rats were allowed free access to rat chow
and tap water.
Daily vaginal smears were taken at 10:00 AM, and the
stage of estrous cycle was determined. Overnight caging of
a proestrous female with a male of proven fertility
induced pregnancy. The next day, the presence of a vaginal
plug or spermatozoa in the vaginal smear was designated
as day 1 of pregnancy.
Collection of embryos
Zygotes, two-cell, four-cell, eight-cell embryos and moru-
lae were flushed with rat 1-cell embryo culture medium
(R1ECM) [16] from oviducts at days 1, 2, 3 and 4 of preg-
nancy, respectively, and blastocysts at day 5 from the uter-
ine horns. All equipment and media used were sterile.
Ovary-oviduct complexes were removed from anesthe-
tized animals. The complexes were placed in R1ECM, and
the oviducts were separated under a dissecting micro-
scope. 30-gauge blunt-end needle attached to a syringe
containing R1ECM was inserted through the oviductal
end held by forceps surrounding the needle and tube.
Embryos were gently flushed into 35-mm-diameter cul-
ture dish. Embryos were washed 3 times by transfer into
fresh R1ECM to remove cell debris and any maternal fac-
tors present in the oviduct.
Zygotes in their cumulus mass were flushed and the
cumulus cells were removed by gentle aspiration through
a micropipette (diameter, 150–200 µm) several times in
R1ECM containing 80 U/mL of hyaluronidase. Clean
zygotes were washed 3 times by transfer into fresh R1ECM
to remove traces of hyaluronidase. Flushed embryos were
collected with a mouth-controlled micropipette (diame-
ter, 150–200 µm).
Blastocysts were flushed from the uterine horns by inser-
tion of a 23-gauge needle attached to a syringe containing
R1ECM. Flushed, free-floating blastocysts were collected
into a polypropylene tube inserted through the vagina
and pushed gently to surround the cervical openings.
Tubes were removed, and their contents were poured into
Petri dishes. Blastocysts were washed and collected as
described for zygotes and embryos. These embryos devel-
oped in vivo were the control groups.Reproductive Biology and Endocrinology 2005, 3:7 http://www.rbej.com/content/3/1/7
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Embryo culture
As described for the in vivo embryos, clean zygotes were
grown in vitro to the same developmental stages as con-
trols; these were the experimental groups. Each group of
embryos consisted of 25–35 embryos collected from six
pregnant females. This was repeated three times for each
developmental stage (total of about 90 embryos per
stage). Groups of 25–35 zygotes were placed into 35-mm-
diameter culture dishes (Nunc, Roskilde, Denmark) con-
taining 50µL of R1ECM medium under a layer of mineral
oil (previously equilibrated to the experimental condi-
tions) and cultured at 37°C under 5% CO2 in air. This
medium was shown by Miyoshi et al. [16] to enable rat
embryo culture to the blastocyst stage. In a comparison of
various media at our laboratory, R1ECM was found to be
the best medium to enable a synchronous development of
embryos (95% of total) to the blastocyst stage. The devel-
oping embryos seemed to be normal in their morphology,
with almost no fragmentation. At the end of incubation,
embryos were washed 3 times with fresh R1ECM.
Embryo immunocytochemistry
The method used was basically that of Dubey et al. [17]
with various modifications. Groups of 20–25 embryos at
different developmental stages from the experimental and
control groups were fixed in 4% paraformaldehyde in
phosphate buffered saline (PBS) at room temperature and
washed twice in PBS, PH 7.4 for 5 minutes. Five percent
bovine serum albumin (BSA) in PBS was used for dilution
of antibodies and washings (PBS-BSA). The embryos were
washed four times in PBS-BSA before immunoreaction.
Embryos, randomly chosen were either exposed to poly-
clonal rabbit anti rodent uPA or rabbit anti rat tPA (Amer-
ican Diagnostics, Pendelton, IN) at a concentration of
4µg/mL. Embryos were then incubated overnight in 50µL
of each antibody solution under paraffin oil in a 35 mm
culture plate in a moist chamber at 4°C. The embryos
were then washed four times in PBS-BSA and incubated
with Cy3-conjugated goat anti-rabbit IgG (Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) at 37°C
for 60 minutes. The conjugated antibody was used at a
dilution of 1:300 in PBS-BSA. After incubation with the
secondary antibody, the embryos were washed again in
PBS-BSA and stained with DNA stain 4', 6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame,
CA) and mounted in Flouromount – G (Southern Bio-
technology Associates, Inc. Birmingham, AL) to minimize
quenching. To confirm that the fluorescence observed was
neither attributable to nonspecific binding of the second-
ary antibody nor to formaldehyde-induced autofluores-
cence, negative controls (without primary antibody) were
established during each immunoreaction procedure. The
immunocytochemistry staining procedure was repeated
three times for each stage of embryo development on dif-
ferent batches of embryos.
Image Analysis
The distribution and concentration of PAs in the embryos
were visualized by fluorescent microscopy on a Zeiss laser
scanning confocal microscope equipped with an X100
objective. Z-sections and XZ-sections were obtained from
3D scanning by using LSM510 software (Zeiss, Feldbach,
Switzerland) The PAs density for each embryo was com-
puted by image analysis based on the same principles as
manual counting described elsewhere [17]. The embryos'
fluorescent images were downloaded using an image
analysis software, ImagJ (NIH, Bethesda, MD). These
images were stored in the computer by use of pixels. All
the slices obtained from 3D scanning were of 0.7µ and
were analyzed by counting the number of pixels of the
Cy3 (red color) in the whole slice. Total pixels in a whole
embryo were calculated by summing the number of pixels
in all the slices of an embryo. This method showed the
total amount of PAs expression in each embryo. The
number of pixels in an embryo represents the intensity of
PAs staining (fluorescence), which is in turn proportional
to the amount of PAs in that embryo. Each experimental
group consisted of 8–10 embryos and the measurements
repeated three times with different batches of embryos
from each developmental stage stained at different times
(total number of 24–30 embryos per stage).
Statistical analysis
Data are expressed as means ± SEM. Statistical analysis
was performed with two-way analysis of variance, fol-
lowed by the least significant differences test for multiple
comparisons using computer software (Statistica 6.0,
Statsoft, Inc. Tulsa, OK). P < 0.05 was defined as statisti-
cally significant difference.
Results
PAs localization
Immunohistochemical staining for the location of tPA
and uPA in preimplantation embryos developed in vivo
and in vitro are shown in figure 1. The PAs were detected
in all stages of embryo development, both in in vivo and
in vitro (Fig. 1A–V). The uPA was expressed in the cell
cytoplasm and plasma membrane (Fig. 1A–K) while tPA
was detected on the cell membrane and in the perivitell-
ine space (Fig. 1L–V). In blastocysts developed in vivo and
in vitro PAs were localized mainly in the trophectoderm
(Fig. 1F, K, Q, V). There was no difference in PAs localiza-
tion comparing in vivo and in vitro developed embryos at
the same stage.
Quantitative measurement of uPA
Quantitative measurement of total uPA in an embryo at
each stage showed significantly lower expression (p <
0.01) in in vitro developed embryos from the 4-cell stage
up to the blastocyst stage compared with the in vivo devel-
oped corresponding timepoint. The highest expression ofReproductive Biology and Endocrinology 2005, 3:7 http://www.rbej.com/content/3/1/7
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PAs localization Figure 1
PAs localization. Expression of uPA (A-K) and tPA (L-V) in preimplantation developing rat embryo stages grown in vivo and 
in vitro. (A, L)-Zygote. (B, G, M, R)-2-cells. (C, H, N, S)-4-cells. (D, I, O, T)-8-cells. (E, J, P, U)-Morula. (F, K, Q, V)-Blastocyst. 
(A-F)-uPA in vivo. (G-K)-uPA in vitro. (L-Q)-tPA in vivo. (R-V)-tPA in vitro. (X)-2-cell uPA negative control. (XX)- 2-cell tPA 
negative control.
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uPA was found in in vivo developed embryos from 4-cell
to the morula stage (90.58, 78.78 and 79.35 Pixels per
embryo × 103, respectively, Fig. 2). In the in vitro devel-
oped embryos, a significant increase (p < 0.01) in uPA
expression was found from the 2-cell stage to the 4-cell
stage (43.91 and 61.86 Pixels per embryo × 103,
respectively).
Quantitative measurement of tPA
Total tPA expression in a whole embryo showed highest
expression in in vivo developed embryos at the 2-cell, 8-
cell, morula and blastocyst stages (61.59, 52.71, 48.03
and 52.34 Pixels per embryo × 103, respectively, Fig. 3). At
the 2-cell stage, morula and blastocyst, a significantly
lower expression (p < 0.01) was found in in vitro devel-
oped embryos as compared with the in vivo ones.
Discussion
Our study demonstrates that uPA and tPA are expressed
throughout all stages of preimplantation development of
rat embryos. Zhang et al. [18] reported expression of uPA
gene and uPA activity in preimplantation rat embryos
developed in vitro and Khamsi et al. [19] reported the
presence of mRNA for uPA in human blastocysts. How-
ever, information about the expression and immunolo-
calization of uPA and tPA has not been reported in in vivo
nor in in vitro preimplantation developing rat embryos.
Quantitative measurement of uPA Figure 2
Quantitative measurement of uPA. Quantitative (Pixels/Embryo) uPA expression in preimplantation rat embryos devel-
oped in vivo and in vitro. Different letters represent statistically significant differences (P < 0.05).
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We present here a quantitative measurement of PAs
expression in a whole embryo allowing comparison of
embryos at different developmental stages, grown in vivo
or in vitro.
The results show localization of immunoreactive uPA in
the embryonic cell cytoplasm and plasma membrane in
all developmental stages both in vivo and in vitro, while
tPA is detected on the cell membrane and in the perivitel-
line space. In the blastocyst stage, PAs are localized mainly
in the trophectoderm. In our previous study [15] we
showed that the activity of uPA was higher than that of
tPA in the blastocyst. Its presence in the trophectoderm
combined with its high activity in this stage, support the
assumption that uPA is important for proper implanta-
tion. This assumption is supported by the study of Kubo
et al. [20] who showed that inhibition of PAs activity pre-
vents the adhesion of mouse embryos to decidual cells
grown in vitro. In addition, trophoblast cells grown in
vitro showed PAs activity at the time of their penetration
into the endometrium in vivo and uPA was the major
enzyme secreted from trophectoderm cells with the high-
est activity on days five to seven of pregnancy [7]. The
exact source(s) of the immunoreactive PAs in in vivo
developing embryos cannot be identified. The serum, ovi-
duct and endometrium could be contributing sources as
Quantitative measurement of tPA Figure 3
Quantitative measurement of tPA. Quantitative (Pixels/Embryo) tPA expression in preimplantation rat embryos devel-
oped in vivo and in vitro. Different letters represent statistically significant differences (P < 0.05).
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suggested in previous studies [10,21-23]. Lack of the these
source(s) in in vitro situation may lead to lower implan-
tation ability of embryos as shown earlier [15].
Pro-uPA is synthesized as an inactive single chain that can
be stored or secreted. The secreted pro-uPA can be cleaved
to produce the two-chain active molecule, uPA, by the aid
of limited proteolytic activity of plasmin [24]. The
secreted pro-uPA or the active uPA can be found free in
cytoplasm and extracellular matrix or bound to a mem-
brane uPA receptor [25]. Whether the uPA identified in
this study is the inactive pro-uPA or the active uPA associ-
ated with the embryonic cell membrane uPA receptor, is
unknown. In our previous work we have shown an
increase in uPA activity towards the blastocyst stage in in
vivo and in in vitro developing embryos [15]. The results
of the present study, showing lower expression of uPA in
the blastocyst stage, may suggest a shift of uPA from the
inactive form to the active form resulting in an increase of
activity despite the reduction in its expression.
High tPA expression was detected at the zygote stage
which is in accordance with high tPA activity found in this
stage [15]. This is supported by the report of Zhang et al.
[18] who showed presence of tPA mRNA in rat oocytes
and two-cell embryos. The embryonic genome of rats and
mice start to be expressed at the 2-cell stage [26] and the
high tPA levels in the zygote are probably due to maternal
mRNA expressed and accumulated in the oocyte [27].
The embryonic extracellular matrix is in a continuous
turnover during the embryonic development. The 8-cell
stage is characterized by structural changes taking place in
the embryo during the compaction process. It is therefore
very likely that such changes at the 8-cell stage could be
associated with increased tPA expression and activity
which is known to participate in tissue remodeling [8].
The high increase in tPA expression from the 4-cell stage
to the 8-cell stage in in vitro developed embryos suggests
de novo synthesis of tPA since there is no extraembryonic
tPA source but the embryos in the culture.
Lower expression of uPA was observed in in vitro devel-
oped embryos as compared with in vivo ones from the 4-
cell up to the blastocyst stage while tPA expression was
lower only in the morula and blastocyst stages. This could
be explained by reduced metabolic activity in the in vitro
developed embryos as suggested by Krisher et al. [28]. In
addition, in vitro conditions may lead to a slower cell divi-
sion rate which may result in a blastocyst comprised of
fewer cells and decreased ability to hatch from the zona
pellucida [28,29]. Carroll et al. [30] showed that the ovi-
duct is also a source of PAs, which could attach to recep-
tors on embryonic cell membrane, and this source is
lacking in in vitro developing embryos. It should be noted
that any culture media would lack maternal factors,
known or yet unknown, which affect embryo develop-
ment and thus, implantation rate, through their effect on
the PA/plasmin system.
Additional studies addressing the regulation of PA/Plas-
min system by adding exogenous factors may provide
insights into its role in early embryo development and
implantation.
Conclusions
The purpose of the study was to determine the relative
importance of tPA and uPA in preimplantation embryo
development. In vitro embryo development leads to
lower PAs expression in a stage dependent manner as
compared with in vivo developing ones. The localization
of both PAs in the blastocysts' trophectoderm supports
the assumption that PAs may play a role in the implanta-
tion process in rats.
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